STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: This compound was found to have the significant activity to block tumor growth through decreased downstream signaling pathways, including MAPK kinase, PI3K, and Stat-3.583 For the sake of drug resistance of tyrosine kinase inhibitors (TKIs) harboring mutations in the BCR-ABL kinase in chronic myelogenous leukemia (CML), several inhibitors like asciminib (ABL001) and GNF-2 were discovered.